In a 73-year-old male with a history of prostate cancer (stage III, Gleason score 7 [3+4]), diabetes mellitus, and hypertension, what is the expected disease progression and how long would it take without treatment?

Natural History of Untreated Stage III Gleason 7 Prostate Cancer

In a 73-year-old man with stage III Gleason 7 (3+4) prostate cancer, without treatment you can expect approximately 10-16 years median survival, with a 29% probability of dying from prostate cancer specifically within 20 years, though competing causes of death from diabetes and hypertension will likely claim him first.

Disease Progression Timeline Without Treatment

Short-term (0-5 years)

• Biochemical progression typically occurs first, with rising PSA levels
• Most men remain asymptomatic during this period
• Local tumor growth continues but rarely causes symptoms initially

Medium-term (5-10 years)

For Gleason 7 disease specifically:

• Disease-specific mean survival of 10 years for Gleason 7 tumors 1
• The distinction between 3+4 versus 4+3 matters significantly - your patient with 3+4 has better prognosis than 4+3 2
• Approximately 40-50% will develop metastatic disease within this timeframe if untreated 3

Long-term (10-20 years)

• 29% probability of prostate cancer death for Gleason 7 disease over 20 years 4
• However, at age 73 with diabetes and hypertension, competing mortality from cardiovascular disease is substantial and may exceed cancer risk 3

Critical Prognostic Factors That Modify This Timeline

PSA kinetics are paramount:

• PSA doubling time <6 months: Dramatically worse prognosis, warrants immediate treatment consideration 5
• PSA doubling time <12 months: High risk of rapid progression 2
• PSA doubling time >15 months: More indolent course, longer survival expected 2

Stage III disease characteristics:

• Locally advanced (T3) disease has worse outcomes than organ-confined
• Presence of seminal vesicle invasion significantly shortens progression-free interval 2

What Actually Happens Without Treatment

Symptom Development Sequence:

1. Years 0-3: Usually asymptomatic, rising PSA only
2. Years 3-7: May develop lower urinary tract symptoms (obstruction, frequency, nocturia)
3. Years 5-10: Risk of bone pain from metastases increases
4. Years 7-15: Potential for spinal cord compression, pathologic fractures, anemia, weight loss

Metastatic Progression:

• Time to clinical metastases: Median 8-10 years for Gleason 7 without treatment 5
• Once metastatic, median survival historically 5-6 years with delayed hormonal therapy 5

The Diabetes and Hypertension Factor

This is crucial context: At 73 years old with diabetes and hypertension, your patient faces significant competing mortality risks. Studies show:

• Men with diabetes on ADT have 2.07-fold higher mortality risk 6
• Cardiovascular disease may kill him before prostate cancer does 3
• The 15-year follow-up data shows many men with Gleason 7 die of other causes, not prostate cancer 3

Clinical Decision Points

When symptoms mandate treatment:

• Baseline PSA >50 ng/mL 2
• PSA doubling time <12 months 2
• Development of bone pain or urinary obstruction 7
• Radiographic evidence of metastases 5

Common Pitfalls to Avoid

1. Don't assume all Gleason 7 behaves the same: 3+4 has significantly better prognosis than 4+3 2, 8
2. Don't ignore PSA kinetics: A rapidly rising PSA (doubling time <6 months) changes everything and demands intervention 5
3. Don't forget competing mortality: At 73 with comorbidities, he may never die from prostate cancer 3
4. Don't wait for symptoms if high-risk features present: PSA doubling time <3 months warrants hormonal therapy even without symptoms 5

The Realistic Prognosis

For your specific patient (73 years, stage III, Gleason 3+4, diabetes, hypertension):

• Best case scenario: Lives 15-20 years, dies of cardiovascular disease, cancer never becomes symptomatic
• Most likely scenario: Develops metastatic disease in 7-10 years, lives 12-15 years total, may or may not die from cancer
• Worst case scenario: Aggressive biology with PSA doubling time <6 months, metastases within 3-5 years, cancer death within 8-10 years

The median overall survival is likely 10-13 years based on his age, comorbidities, and cancer characteristics 3, 1, with prostate cancer being the cause of death in roughly 30% of cases 4.